There are various ongoing clinical trials using CAR T cell technology to target myeloma antigens such as B cell maturation antigen (BCMA), CD138, CS1 glycoprotein antigen (SLAMF7) and immunoglobulin light chains [31–35] (Table 1). This evidence concerns the gene TNFRSF17 and plasma cell myeloma.